Autologous Dendritic Cells, Metronomic Cyclophosphamide and Checkpoint Blockade in Children With Relapsed HGG
Status:
Recruiting
Trial end date:
2024-04-30
Target enrollment:
Participant gender:
Summary
This phase I/II trials evaluates the feasibility, safety and efficacy of an individualized
cancer vaccine, based on autologous, tumor-lysate loaded dendritic cells in children and
adolescents with relapsed high-grade gliomas. In addition, regulatory T cells are depleted by
a short cycle of metronomic cyclophosphamide upfront of the vaccine in order to facilitate
induction of immune responses.
Therapeutic DC vaccines are followed by four cycles of Nivo/Ipi double checkpoint blockade
and a Nivolumab monotherapy maintenance in order to optimize the induced T-cell response.